Every 8-K that Caribou Biosciences, Inc. (CRBU) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CRBU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRBU filings page.
Caribou Biosciences, Inc. reported second quarter 2026 results and updated progress on its allogeneic CAR‑T pipeline. For vispacabtagene regedleucel (vispa‑cel) in second‑line large B cell lymphoma, ANTLER phase 1 data in 27 optimized patients showed an 82% overall response rate, 67% complete response rate, and 17.1‑month median progression‑free survival, with a generally well‑tolerated safety profile. The company plans a pivotal ANTLER‑3 phase 3 trial enrolling about 250 CD19‑naïve 2L LBCL patients.
For CB‑011 in relapsed or refractory multiple myeloma, CaMMouflage phase 1 dose‑escalation data at the 450‑million‑cell dose in 12 BCMA‑naïve patients showed a 92% overall response rate, 83% ≥CR rate, and 91% MRD negativity, with durable responses after a single dose. Caribou is enrolling BCMA‑naïve and BCMA‑exposed patients in dose expansion, with initial expansion data expected in the second half of 2026.
Financially, second‑quarter 2026 licensing and other revenue was $1.5 million versus $2.7 million a year earlier. Research and development expenses fell to $18.9 million from $27.7 million, and general and administrative expenses declined to $7.9 million from $10.4 million. GAAP net loss narrowed to $24.3 million, or $0.24 per share, compared with $54.1 million, or $0.58 per share, which previously included $21.3 million in non‑cash impairment charges. Cash, cash equivalents, and marketable securities totaled $113.8 million as of June 30, 2026, and the company expects this to fund its current operating plan, including CB‑011 dose expansion and ANTLER‑3 start‑up activities, to the end of 2027.
Caribou Biosciences, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected three Class II directors — Andrew Guggenhime, David Johnson, and Nancy Whiting — to serve until the 2029 annual meeting.
They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. An amendment to the certificate of incorporation to provide for officer exculpation from certain fiduciary duty claims did not receive sufficient support and was not approved. Stockholders approved a proposal to permit adjournment of the meeting if necessary, although the company chose not to adjourn.
Caribou Biosciences reported updated clinical data for two off-the-shelf CAR-T cell therapies in blood cancers. In the ANTLER phase 1 trial for second-line large B cell lymphoma, the optimized vispa-cel subgroup (27 patients) showed an 82% overall response rate, 67% complete response rate, and 17.1-month median progression-free survival after a single 80 million-cell dose, with a generally manageable safety profile but including two treatment-related deaths. These data support the design of the planned ANTLER-3 pivotal phase 3 trial in about 250 CD19‑naïve second-line patients.
In the CaMMouflage phase 1 trial for relapsed or refractory multiple myeloma, 12 BCMA‑naïve patients treated at the recommended 450 million-cell dose of CB-011 had a 92% overall response rate, 83% complete or stringent complete response rate, 91% minimal residual disease negativity among evaluable patients, and 50% remaining in complete response or better at 15 months, with one CB‑011‑related death reported across all treated patients. Caribou plans to present these results at the EHA 2026 meeting and expects initial dose expansion data for CB‑011 in the second half of 2026.
Caribou Biosciences reported first quarter 2026 results and highlighted key progress in its allogeneic CAR-T programs. Licensing and other third-party revenue was $2.4 million for the three months ended March 31, 2026, essentially unchanged from $2.4 million a year earlier.
Research and development expenses fell to $20.6 million from $35.5 million, and general and administrative expenses declined to $8.1 million from $9.7 million, reflecting prior workforce reductions and pipeline prioritization. Net loss narrowed to $25.1 million, or $0.26 per share, compared with a $40.0 million loss, or $0.43 per share, in 2025.
Caribou ended the quarter with $118.6 million in cash, cash equivalents, and marketable securities and expects this to fund its current operating plan, including CB-011 dose expansion and start-up activities for the planned pivotal vispa-cel trial, into the second half of 2027. The company also reported FDA alignment on the pivotal ANTLER-3 phase 3 design for vispa-cel and RMAT designation for CB-011 based on promising phase 1 data.
Caribou Biosciences reported that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The designation is based on phase 1 CaMMouflage trial dose-escalation data in a 12-patient BCMA-naïve cohort, which showed a 92% overall response rate, a 75% complete response or better rate, and 91% minimal residual disease negativity at the recommended expansion dose. Forty-eight patients have been treated in dose escalation, and the ongoing dose expansion is testing a 450x106 CAR-T cell dose in both BCMA-naïve and BCMA-exposed patients, with additional data expected in 2026. CB-011 has shown a manageable safety profile, with common treatment-emergent adverse events including neutropenia, anemia, thrombocytopenia, infections, and cytokine release syndrome.
Caribou Biosciences reported fourth quarter and full year 2025 results while highlighting progress in its allogeneic CAR-T pipeline. Licensing and collaboration revenue was $3.9 million in Q4 2025 and $11.2 million for 2025, up from $2.1 million and $10.0 million in 2024, mainly from prior IP licenses.
Research and development expenses fell to $109.4 million for 2025 from $130.2 million in 2024, and general and administrative expenses declined to $37.9 million from $46.5 million, reflecting workforce reductions and pipeline prioritization. The company recorded $21.3 million of non-recurring, non-cash impairment charges in 2025.
GAAP net loss was $26.5 million (or $0.28 per share) in Q4 2025 and $148.1 million (or $1.59 per share) for 2025. Non-GAAP net loss for 2025, excluding impairment charges, was $126.8 million (or $1.36 per share). Caribou held $142.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025 and expects this to fund its current operating plan, including CB-011 dose expansion and certain start-up activities for a planned vispa-cel pivotal trial, into 2H 2027.
Caribou Biosciences (CRBU) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025, and a business update. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act.
Caribou Biosciences (CRBU) reported preliminary cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025. The company also released new clinical data for its allogeneic CAR-T programs and outlined a pivotal plan for vispacabtagene regedleucel (vispa-cel).
In the ANTLER phase 1 trial’s 2L LBCL confirmatory cohort (N=22) with partial HLA matching and dosing at 80x10^6 cells, vispa-cel showed an 82% overall response rate (18/22), 64% complete response (14/22), and 51% 12‑month PFS at a 6.0‑month median follow-up. An optimized cohort (N=35) reported 86% ORR (30/35), 63% CR (22/35), and 53% 12‑month PFS at 11.8 months’ median follow‑up. Safety showed common TEAEs typical of CAR‑T; there were no GvHD cases, no grade ≥3 ICANS, fewer than 5% grade ≥3 CRS, and one vispa‑cel–related grade 5 IEC‑HS.
The company plans a randomized, controlled pivotal phase 3 in approximately 250 2L LBCL CD19‑naïve patients ineligible for transplant and autologous CAR‑T, with PFS as the primary endpoint. In multiple myeloma, CB‑011 dose escalation identified a recommended dose (450x10^6); in a 12‑patient BCMA‑naïve cohort at this dose, responses included 92% ORR (11/12), 75% CR/sCR (9/12), and 91% (10/11) MRD‑negativity at 8.3 months’ median follow‑up, with a manageable safety profile.
Caribou Biosciences, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference into the disclosure.
The filing specifies that the Item 2.02 information (including Exhibit 99.1) is being furnished and therefore is not deemed "filed" under the Exchange Act, meaning it is provided for investor information without extending Section 18 liabilities. The 8-K itself does not include separate financial tables or statements beyond the furnished press release.